Clinical Trials Logo

Clinical Trial Summary

An International, Single-Arm, Multicenter Phase 2 Trial.

Clinical Trial Description

This is an international, single-arm, multicenter phase 2 trial, in patients ≥ 12 months of age with high-risk NB with primary refractory disease or in first relapse. Patients will receive naxitamab + GM-CSF + irinotecan/temozolomide. The Follow-Up period ends 2 years after End of Treatment. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04560166
Study type Interventional
Source Y-mAbs Therapeutics
Status Terminated
Phase Phase 2
Start date November 8, 2021
Completion date September 21, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03242603 - Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells Phase 1/Phase 2
Recruiting NCT04903899 - 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma Phase 2
Completed NCT02139397 - Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma Phase 1/Phase 2
Recruiting NCT04239092 - 9-ING-41 in Pediatric Patients With Refractory Malignancies. Phase 1
Recruiting NCT03373097 - Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors Phase 1/Phase 2
Recruiting NCT05754684 - Quadruple Immunotherapy for Neuroblastoma Phase 2
Completed NCT01467986 - Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma Phase 2
Completed NCT02258815 - CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma Phase 2